JP7000315B2 - 高結合活性ｈｐｖ ｔ細胞受容体 - Google Patents

高結合活性ｈｐｖ ｔ細胞受容体 Download PDF

Info

Publication number
JP7000315B2
JP7000315B2 JP2018519710A JP2018519710A JP7000315B2 JP 7000315 B2 JP7000315 B2 JP 7000315B2 JP 2018519710 A JP2018519710 A JP 2018519710A JP 2018519710 A JP2018519710 A JP 2018519710A JP 7000315 B2 JP7000315 B2 JP 7000315B2
Authority
JP
Japan
Prior art keywords
seq
cdr3
cdr2
cdr1
sequences contained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018519710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535668A (ja
JP2018535668A5 (enExample
Inventor
ブランケンシュタイン，トーマス
ウィリンズキー，ゲラルド
Original Assignee
マックス－デルブリュック－ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ－ゲマインシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マックス－デルブリュック－ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ－ゲマインシャフト filed Critical マックス－デルブリュック－ツェントルム フューア モレキュラーレ メディツィン イン デア ヘルムホルツ－ゲマインシャフト
Publication of JP2018535668A publication Critical patent/JP2018535668A/ja
Publication of JP2018535668A5 publication Critical patent/JP2018535668A5/ja
Application granted granted Critical
Publication of JP7000315B2 publication Critical patent/JP7000315B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018519710A 2015-10-16 2016-10-13 高結合活性ｈｐｖ ｔ細胞受容体 Expired - Fee Related JP7000315B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15190230.1 2015-10-16
EP15190230.1A EP3156067A1 (en) 2015-10-16 2015-10-16 High avidity hpv t-cell receptors
PCT/EP2016/074612 WO2017064198A1 (en) 2015-10-16 2016-10-13 High avidity hpv t-cell receptors

Publications (3)

Publication Number Publication Date
JP2018535668A JP2018535668A (ja) 2018-12-06
JP2018535668A5 JP2018535668A5 (enExample) 2019-11-21
JP7000315B2 true JP7000315B2 (ja) 2022-02-04

Family

ID=54359849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519710A Expired - Fee Related JP7000315B2 (ja) 2015-10-16 2016-10-13 高結合活性ｈｐｖ ｔ細胞受容体

Country Status (7)

Country Link
US (1) US11401316B2 (enExample)
EP (2) EP3156067A1 (enExample)
JP (1) JP7000315B2 (enExample)
CN (1) CN108135998B (enExample)
AU (1) AU2016336817C1 (enExample)
CA (1) CA3001395A1 (enExample)
WO (1) WO2017064198A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43380A (fr) 2015-12-03 2018-10-10 Juno Therapeutics Inc Récepteurs chimériques modifiés et compositions et procédés associés
DE102017114737A1 (de) 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
BR112020006643A2 (pt) 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
CN109053879B (zh) * 2018-08-22 2020-12-25 深圳市宝安区中心医院 一种治疗宫颈癌的scFv抗体及其应用
CN113811329B (zh) 2019-04-19 2025-10-14 天科雅生物科技有限公司 抗pd-1抗体和其用途
CN113072635B (zh) * 2020-01-06 2023-08-25 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的t细胞受体及其编码序列
WO2021155518A1 (en) * 2020-02-05 2021-08-12 Tcrcure Biopharma Corp Anti-hpv t cell receptors and engineered cells
CN113321726B (zh) * 2020-02-28 2024-05-28 香雪生命科学技术（广东）有限公司 一种识别hpv的t细胞受体
AU2021243742A1 (en) * 2020-03-23 2022-11-10 The Council Of The Queensland Institute Of Medical Research Compositions and methods for targeting HPV-infected cells
CA3186594A1 (en) * 2020-06-09 2021-12-16 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
CN113801217B (zh) * 2020-06-17 2025-12-23 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的高亲和力t细胞受体
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
CN114539385A (zh) * 2020-11-26 2022-05-27 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的tcr
CN114853878A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术（广东）有限公司 一种针对hpv的高亲和力tcr
JP2024509853A (ja) 2021-03-03 2024-03-05 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法およびｄｇｋ阻害剤の組合せ
WO2023014337A1 (en) * 2021-08-04 2023-02-09 GUERRERO PRESTON Rafael Viral and host biomarkers for early detection, therapeutic effectiveness, and relapse monitoring of cancer linked to severe acute respiratory syndrome coronavirus 2 and human papilloma virus
CN116262779A (zh) * 2021-12-14 2023-06-16 深圳先进技术研究院 一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法
CN117402232A (zh) * 2022-05-10 2024-01-16 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
CN115286690B (zh) * 2022-05-10 2023-06-20 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
JP2025531850A (ja) 2022-09-08 2025-09-25 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
GB202311170D0 (en) * 2023-07-20 2023-09-06 Univ Oxford Innovation Ltd Antigen binding polypeptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070218080A1 (en) 2006-03-14 2007-09-20 Mackay Memorial Hospital Peptide antigen of human papillomavirus type 16 and application thereof
US20120121628A1 (en) 2010-11-15 2012-05-17 National Health Research Institutes Lipidated polyepitope vaccines
JP2015504895A (ja) 2012-01-13 2015-02-16 エーピーオー‐ティー ビー．ヴイ． 毒性部分を備える異常細胞拘束性免疫グロブリン
US20150175683A1 (en) 2012-06-26 2015-06-25 Apo-T B.V. Binding molecules targeting pathogens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2009042570A2 (en) * 2007-09-25 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
BR122020026648B1 (pt) * 2010-09-20 2021-12-07 Biontech Cell & Gene Therapies Gmbh Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo
JP6628719B2 (ja) * 2013-07-15 2020-01-15 アメリカ合衆国 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体
GB201322430D0 (en) * 2013-12-18 2014-02-05 Immunocore Ltd T cell receptors
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070218080A1 (en) 2006-03-14 2007-09-20 Mackay Memorial Hospital Peptide antigen of human papillomavirus type 16 and application thereof
US20120121628A1 (en) 2010-11-15 2012-05-17 National Health Research Institutes Lipidated polyepitope vaccines
JP2015504895A (ja) 2012-01-13 2015-02-16 エーピーオー‐ティー ビー．ヴイ． 毒性部分を備える異常細胞拘束性免疫グロブリン
US20150175683A1 (en) 2012-06-26 2015-06-25 Apo-T B.V. Binding molecules targeting pathogens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Genome Medicine，2013年，Vol.5:98，pp.1-13

Also Published As

Publication number Publication date
CN108135998B (zh) 2023-05-09
CN108135998A (zh) 2018-06-08
US20190062398A1 (en) 2019-02-28
EP3156067A1 (en) 2017-04-19
WO2017064198A1 (en) 2017-04-20
EP3362090A1 (en) 2018-08-22
AU2016336817B2 (en) 2021-02-04
JP2018535668A (ja) 2018-12-06
AU2016336817C1 (en) 2021-05-13
AU2016336817A1 (en) 2018-05-31
AU2016336817B9 (en) 2021-02-11
US11401316B2 (en) 2022-08-02
CA3001395A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
JP7000315B2 (ja) 高結合活性ｈｐｖ ｔ細胞受容体
JP7744479B2 (ja) 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体
JP7755890B2 (ja) Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞
JP6964351B2 (ja) 新規ｔ細胞受容体およびそれを用いた免疫療法
CA2918216C (en) Anti-human papillomavirus 16 e6 t cell receptors
WO2019109980A1 (zh) 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
KR20190132655A (ko) T 세포 수용체, 및 이를 사용하는 흑색종의 우선적 발현 항원(prame) 양성 암에 대한 면역 요법
WO2017219936A1 (zh) 一种高效稳定表达激活型抗体的car-t细胞及其用途
JP2017508466A (ja) キメラ抗原受容体
CN115073583A (zh) 识别hla-cw8限制性突变kras的t细胞受体
CN114591444A (zh) 一种基于cd7的人源化嵌合抗原受体及其应用
JP2021500866A (ja) 改変ｃａｒ−ｔ
CN107108752A (zh) 基于t细胞的免疫治疗药
EP3735425A1 (en) Chimeric antigen receptor specific for bdca2 antigen
WO2023051361A1 (zh) 工程化免疫细胞及其用途
CN112041432A (zh) Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
WO2023035947A1 (zh) 工程化免疫细胞及其用途
CN114891123A (zh) 一种基于CD79b人源化抗体的嵌合抗原受体及其应用
WO2023071811A1 (zh) 工程化免疫细胞及其用途
WO2023083003A1 (zh) 工程化免疫细胞及其用途
HK40034163A (en) Genetically engineered cell and application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210414

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211223

R150 Certificate of patent or registration of utility model

Ref document number: 7000315

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees